Affordable Access

Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors.

Authors
  • Sahebjam, Solmaz1
  • Stallworth, Dexter G
  • Mokhtari, Sepideh
  • Tran, Nam D
  • Arrington, John A
Type
Published Article
Journal
Cancer control : journal of the Moffitt Cancer Center
Publication Date
Apr 01, 2017
Volume
24
Issue
2
Pages
180–186
Identifiers
PMID: 28441372
Source
Medline
License
Unknown

Abstract

Although immunotherapy Response Assessment for Neuro-Oncology criteria have been developed to assist with response assessment of high-grade gliomas to immunotherapy and to provide guidance with treatment decisions, these criteria have not been validated in prospective clinical trials. In patients with brain tumors who are receiving immunotherapy, MRI findings suggestive of disease progression should be evaluated with caution to prevent premature discontinuation of potentially beneficial therapies. Close, clinical monitoring with appropriate short-term, follow-up imaging is often necessary, and histopathological analysis may be required in some cases to confirm disease progression before a decision on continuation of these novel therapies can accurately be made.

Report this publication

Statistics

Seen <100 times